Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Preemption Redux: Can Juries Deem A Drug Too Dangerous?

Executive Summary

Supreme Court will decide in Mutual Pharmaceutical v. Bartlett whether generic drug manufacturers can be sued for alleged design defects; at issue is whether a jury can determine that a drug’s risks outweigh its benefits.


Related Content

Preemption Preference: Supreme Court Seems Wary Of Having Jurors Override FDA Safety Decisions
FDA May Drop Generic Liability Shield, Allow ANDA Manufacturers To Change Labels
Post-Mensing Blues: Generic Mfrs. Still Face Product Liability Claims
Generic Firms Get Supreme Shield From Product Liability, But Court Hints At Reg Change
Pre-emption After Supreme Court Ruling May Depend On How FDA Weighs Risk
Rx Injury Claims May Grow After Court Finds Brand Liable For Generic Problems


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts